Even though cancer cells use multiple metabolic methods to subvert immune cells from their fundamental role (lactate; IDO, HIF1-α, and probably others), targeting these metabolic pathways together with immune checkpoint inhibitors might, in some settings, improve the clinical response. Here, IDO1 is linked to cancer.